Search
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigationalVilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnBinding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: ADDAMEL N, ADDAMEL NSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMethylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalMethylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Afr...
Mixtures: UR N-C Urinary AntisepticCategories: P-glycoprotein inhibitors, P-glycoprotein substratesUbidecarenone
go.drugbank.com/drugs/DB09270ApprovedInvestigationalNutraceuticalUbidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid...
Categories: P-glycoprotein substratesLevobetaxolol
go.drugbank.com/drugs/DB09351ApprovedLevobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesEsterified estrogens
go.drugbank.com/drugs/DB09381ApprovedEsterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterifi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates